Predictive model for microvascular invasion of hepatocellular carcinoma among candidates for either hepatic resection or liver transplantation.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
06 2019
Historique:
received: 30 08 2018
revised: 05 01 2019
accepted: 21 01 2019
pubmed: 18 3 2019
medline: 4 1 2020
entrez: 18 3 2019
Statut: ppublish

Résumé

Microvascular invasion is the strongest prognostic factor of survival in patients with hepatocellular carcinoma. We therefore developed a predictive model for microvascular invasion of hepatocellular carcinoma to help guide treatment strategies in patients scheduled for either hepatic resection or liver transplantation. Patients with hepatocellular carcinoma who underwent hepatic resection or liver transplantation from 1994 to 2016 were divided into training and validation cohorts. A predictive model for microvascular invasion was developed based on microvascular invasion risk factors in the training cohort and validated in the validation cohort. A total of 910 patients (425 having received hepatic resection, 485 having received liver transplantation) were included in the training (n = 637) and validation (n = 273) cohorts. Multivariate analysis identified α-fetoprotein ≥100 ng/mL (relative risk 3.05, P < .0001), tumor size ≥40 mm (relative risk 1.98, P = .0002), nonboundary hepatocellular carcinoma type (relative risk 1.91, P = .001), neutrophil-to-lymphocyte ratio (relative risk 1.86, P = .002), and aspartate aminotransferase (relative risk 1.53, P = .02) as associated with microvascular invasion. The estimated probability of microvascular invasion ranged from 17.0% in patients with none of these factors to 86.9% in the presence of all factors. This model achieved a C-index of 0.732 in the validation cohort. The 5-year overall survival of patients with ≥50% probability of microvascular invasion was poorer than that of patients with <50% probability (hepatic resection; 39.1% vs 61.2%, P < .0001, liver transplantation; 5-year overall survival, 54.8% vs 79.0%, P = .05). This model developed from preoperative data allows reliable prediction of microvascular invasion in candidates for either hepatic resection or liver transplantation.

Sections du résumé

BACKGROUND
Microvascular invasion is the strongest prognostic factor of survival in patients with hepatocellular carcinoma. We therefore developed a predictive model for microvascular invasion of hepatocellular carcinoma to help guide treatment strategies in patients scheduled for either hepatic resection or liver transplantation.
METHODS
Patients with hepatocellular carcinoma who underwent hepatic resection or liver transplantation from 1994 to 2016 were divided into training and validation cohorts. A predictive model for microvascular invasion was developed based on microvascular invasion risk factors in the training cohort and validated in the validation cohort.
RESULTS
A total of 910 patients (425 having received hepatic resection, 485 having received liver transplantation) were included in the training (n = 637) and validation (n = 273) cohorts. Multivariate analysis identified α-fetoprotein ≥100 ng/mL (relative risk 3.05, P < .0001), tumor size ≥40 mm (relative risk 1.98, P = .0002), nonboundary hepatocellular carcinoma type (relative risk 1.91, P = .001), neutrophil-to-lymphocyte ratio (relative risk 1.86, P = .002), and aspartate aminotransferase (relative risk 1.53, P = .02) as associated with microvascular invasion. The estimated probability of microvascular invasion ranged from 17.0% in patients with none of these factors to 86.9% in the presence of all factors. This model achieved a C-index of 0.732 in the validation cohort. The 5-year overall survival of patients with ≥50% probability of microvascular invasion was poorer than that of patients with <50% probability (hepatic resection; 39.1% vs 61.2%, P < .0001, liver transplantation; 5-year overall survival, 54.8% vs 79.0%, P = .05).
CONCLUSION
This model developed from preoperative data allows reliable prediction of microvascular invasion in candidates for either hepatic resection or liver transplantation.

Identifiants

pubmed: 30878140
pii: S0039-6060(19)30043-1
doi: 10.1016/j.surg.2019.01.012
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1168-1175

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Hidetoshi Nitta (H)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France; Departement of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Japan. Electronic address: hnitta5085@gmail.com.

Marc-Antoine Allard (MA)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France.

Mylène Sebagh (M)

Departement of Pathology, Hôpital Paul Brousse, Assistance Publique-Hôpitaux de Paris, Villejuif, France.

Vincent Karam (V)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France.

Oriana Ciacio (O)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France.

Gabriella Pittau (G)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France.

Eric Vibert (E)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France.

Antonio Sa Cunha (A)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France.

Daniel Cherqui (D)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France.

Denis Castaing (D)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France.

Henri Bismuth (H)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France.

Catherine Guettier (C)

Departement of Pathology, Bicêtre University Hospital, Université Paris-Sud, Le Kremlin-Bicêtre, Ile-de-France, France.

Didier Samuel (D)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France.

Hideo Baba (H)

Departement of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Japan.

René Adam (R)

Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Université Paris-Sud, Inserm U 935 and U 1193, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH